Osaka, Japan – February 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for three compounds with six strengths ... Read More
Forty Awardees Chosen for Their Outstanding Role in Advancing Patient Care
Maple Grove, MN – February 6, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are pleased to recognize the ... Read More
Pharmaceutical Company Highlights Past Achievements, Future Endeavors
Maple Grove, MN – January 28, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith), a US- based pharmaceutical company that has successfully delivered medications to the people who need them for ... Read More
Osaka, Japan – January 9, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Osaka, Japan – December 13, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of six compounds with 14 strengths of generic drugs. They will be ... Read More
Osaka, Japan – December 5, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for RISEDRONATE SODIUM Tablets 17.5 mg [SAWAI]* and DOBUTAMINE HYDROCHLORIDE I.V. Infusion 100 mg [SAWAI]**.
This ... Read More
Osaka, Japan –November 21, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for LEVOFOLINATE I.V. Infusion 25 mg [SAWAI] and 100 mg [SAWAI]*.
This approval expands the indication of LEVOFOLINATE I.V. Infusion 25 mg [SAWAI] and 100 mg [SAWAI] to include the ... Read More
QUDEXY® XR’S ACCESS PATHWAYS® PROGRAM PLATINUM PASS™ FEATURED AT BOOTH #415
Maple Grove, MN – October 25, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the American Academy of Neurology (AAN) ... Read More
Clobazam Tablets, CIV, 10 and 20 mg Clobazam Oral Suspension, CIV, 2.5 mg/mL Upsher-Smith Laboratories, LLC
Maple Grove, MN – October 23, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Clobazam Tablets, CIV, 10 ... Read More
